Hamburg, Germany, and Sydney, Australia, September 2, 2026
Evotec SE and Plectonic Biotech have entered into a research collaboration to explore a new generation of T-cell-engaging approaches for the treatment of solid tumors. The collaboration combines Evotec’s integrated drug-discovery capabilities and oncology expertise with Plectonic’s proprietary TriTAC™ platform, which is designed to generate multispecific molecules capable of directing T cells toward tumor cells. The companies will investigate novel therapeutic concepts intended to address challenges associated with existing T-cell engager approaches, including tumor heterogeneity, target expression and the need to achieve effective immune-cell activation within solid tumor microenvironments. The collaboration represents a further expansion of next-generation cancer immunotherapy research, with the partners seeking to identify and advance differentiated therapeutic candidates through preclinical development.
Evotec and Plectonic Combine Drug Discovery Platforms
Under the research collaboration, Evotec and Plectonic will work together to explore selected tumor targets using Plectonic’s proprietary multispecific antibody technology. Plectonic’s TriTAC platform is designed around a compact molecular architecture that can engage tumor-associated targets and T cells simultaneously, potentially enabling targeted immune activation against malignant cells. By combining multiple functional binding domains within a single molecule, the approach is intended to provide opportunities for designing T-cell-engaging therapeutics with differentiated properties compared with conventional bispecific formats. The collaboration allows the partners to apply this technology to solid-tumor targets where effective immune-cell redirection remains an important area of therapeutic research. Evotec contributes an established integrated drug-discovery platform, including target identification, assay development, screening, medicinal chemistry, protein science and preclinical development capabilities. The company has extensive experience working across oncology and other therapeutic areas and provides infrastructure intended to move promising biological concepts toward development candidates. Plectonic contributes its specialized T-cell engager technology, allowing the collaboration to combine platform innovation with broader discovery and translational capabilities. This model reflects a growing trend in biopharmaceutical research in which platform biotechnology companies partner with larger drug-discovery organizations to accelerate development of novel therapeutic modalities.
TriTAC Platform Targets Solid Tumor Challenges
Developing effective T-cell engagers for solid tumors remains challenging because solid cancers differ substantially from hematological malignancies. Tumor cells may display heterogeneous levels of target proteins, while the tumor microenvironment can suppress immune activity and restrict penetration of therapeutic molecules. Researchers are therefore investigating multispecific formats capable of improving tumor-cell recognition and T-cell recruitment and activation while maintaining an acceptable safety profile. Plectonic’s TriTAC platform is being explored as one potential approach to address these challenges through molecular designs intended to engage both tumor-associated antigens and immune effector cells. The companies expect the research program to generate novel T-cell-engaging molecules directed against selected solid-tumor targets. At this stage, the collaboration is focused on research and discovery rather than clinical development, meaning that any resulting candidates would need to undergo extensive preclinical characterization, pharmacological evaluation, toxicology studies and regulatory development before potential human trials. The collaboration nevertheless provides a pathway for assessing whether Plectonic’s technology can produce differentiated molecules against clinically relevant oncology targets.
Advertisement
Collaboration Advances Next-Generation Cancer Immunotherapy
The partnership reflects the broader pharmaceutical industry’s interest in multispecific antibodies and immune-cell engagers as a strategy for developing cancer therapies beyond traditional monoclonal antibodies. T-cell-engaging therapies have demonstrated the ability to redirect the body’s immune cells toward malignant cells, but expanding these approaches into solid tumors requires careful optimization of target selection, molecular architecture, tissue distribution, potency and safety. New platform technologies could potentially help researchers develop molecules with improved characteristics for particular tumor types and biological targets. For cGxP.wire readers, the collaboration is significant because it highlights the convergence of biopharmaceutical drug discovery, multispecific antibody engineering and cancer immunotherapy. Evotec and Plectonic are combining complementary technologies to investigate therapeutic concepts that could eventually produce new candidates for solid-tumor treatment. The agreement also illustrates the role of strategic research partnerships in translating emerging biotechnology platforms into potential pharmaceutical development programs. Any therapeutic candidates arising from the collaboration will remain subject to further research and development, and the announcement does not indicate that a resulting therapy has entered clinical trials or received regulatory approval.
Source: Evotec, Plectonic Biotech press release
